Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Celltrion, Inc. (068270.KS)
Incheon, KR
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.45% | -6.62% | -2.41% | -19.96% | -2.36% | -5.93% | +28.40% | +23.38% | -16.73% | +145.89% | +3,093.38% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 9 | 0 |
| Buy | 12 | -1 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Biotechnology: +1.6%+17.0% ★ Q1'26: +36.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+127.1% ★ Q1'26: +194.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+15.6% ★ Q1'26: +8.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+28.1% ★ Q1'26: +28.1% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+5.3% ★ Q1'26: +5.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+6.4% Q1'26: +13.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×2.57× Q1'26: 2.90× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 19 Rev. Ana. 20 EPS Ana. |
Dec 2027 22 Rev. Ana. 22 EPS Ana. |
Dec 2028 10 Rev. Ana. 11 EPS Ana. |
Dec 2029 15 Rev. Ana. 14 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
603.41B
est: 568.93B (+6.1%)
|
670.58B
est: 639.80B (+4.8%)
|
949.08B
est: 948.19B (+0.1%)
|
982.07B
est: 1.00T (-2.3%)
|
1.13T
est: 1.11T (+1.3%)
|
1.85T
est: 1.86T (-0.5%)
|
1.89T
est: 1.88T (+0.8%)
|
2.28T
est: 2.36T (-3.2%)
|
2.18T
est: 2.28T (-4.6%)
|
3.56T
est: 3.51T (+1.4%)
|
4.16T
est: 4.14T (+0.4%)
|
5.32T
5.17T – 5.68T
+28.3% YoY
|
6.13T
5.70T – 6.67T
+15.3% YoY
|
6.90T
6.55T – 7.44T
+12.5% YoY
|
6.83T
6.48T – 7.36T
-1.0% YoY
|
| EBITDA |
274.79B
est: 232.23B (+18.3%)
|
331.52B
est: 261.16B (+26.9%)
|
597.48B
est: 387.04B (+54.4%)
|
447.55B
est: 410.19B (+9.1%)
|
546.58B
est: 454.55B (+20.2%)
|
835.87B
est: 758.79B (+10.2%)
|
958.32B
est: 767.05B (+24.9%)
|
801.91B
est: 963.54B (-16.8%)
|
937.76B
est: 931.36B (+0.7%)
|
1.07T
est: 1.36T (-21.3%)
|
1.45T
est: 1.61T (-9.6%)
|
2.06T
2.00T – 2.20T
+28.3% YoY
|
2.38T
2.21T – 2.59T
+15.3% YoY
|
2.67T
2.54T – 2.88T
+12.5% YoY
|
2.65T
2.51T – 2.85T
-1.0% YoY
|
| EBIT |
192.62B
est: 173.70B (+10.9%)
|
242.84B
est: 195.34B (+24.3%)
|
497.74B
est: 289.49B (+71.9%)
|
316.38B
est: 306.81B (+3.1%)
|
392.86B
est: 339.99B (+15.6%)
|
662.06B
est: 567.55B (+16.7%)
|
746.85B
est: 573.73B (+30.2%)
|
626.62B
est: 720.70B (-13.1%)
|
692.08B
est: 696.63B (-0.7%)
|
651.69B
est: 1.02T (-35.8%)
|
1.17T
est: 1.20T (-2.7%)
|
1.54T
1.50T – 1.64T
+28.3% YoY
|
1.78T
1.65T – 1.93T
+15.3% YoY
|
2.00T
1.90T – 2.16T
+12.5% YoY
|
1.98T
1.88T – 2.13T
-1.0% YoY
|
| Net Income |
154.09B
est: 221.67B (-30.5%)
|
177.99B
est: 266.52B (-33.2%)
|
368.22B
est: 560.95B (-34.4%)
|
245.76B
est: 409.64B (-40.0%)
|
301.03B
est: 418.77B (-28.1%)
|
517.76B
est: 814.72B (-36.4%)
|
579.46B
est: 828.33B (-30.0%)
|
537.84B
est: 841.10B (-36.1%)
|
535.65B
est: 857.29B (-37.5%)
|
422.69B
est: 425.73B (-0.7%)
|
1.03T
est: 905.56B (+13.9%)
|
1.49T
1.40T – 1.59T
+64.5% YoY
|
1.72T
1.41T – 2.19T
+15.4% YoY
|
2.05T
1.92T – 2.26T
+19.4% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
39.72B
est: 40.75B (-2.5%)
|
45.60B
est: 45.83B (-0.5%)
|
75.54B
est: 67.92B (+11.2%)
|
63.42B
est: 71.98B (-11.9%)
|
70.62B
est: 79.77B (-11.5%)
|
57.48B
est: 133.16B (-56.8%)
|
103.93B
est: 134.61B (-22.8%)
|
120.14B
est: 169.09B (-28.9%)
|
198.36B
est: 163.44B (+21.4%)
|
456.88B
est: 401.84B (+13.7%)
|
1.02T
est: 474.89B (+115.6%)
|
609.41B
592.87B – 650.68B
+28.3% YoY
|
702.86B
653.47B – 764.65B
+15.3% YoY
|
790.61B
750.93B – 852.68B
+12.5% YoY
|
782.36B
743.09B – 843.78B
-1.0% YoY
|
| EPS |
1,046.64
est: 1,021.53 (+2.5%)
|
1,104.05
est: 1,228.17 (-10.1%)
|
2,550.83
est: 2,584.97 (-1.3%)
|
1,700.53
est: 1,887.72 (-9.9%)
|
2,084.07
est: 1,929.79 (+8.0%)
|
3,277.50
est: 3,754.44 (-12.7%)
|
3,663.00
est: 3,817.13 (-4.0%)
|
3,894.00
est: 3,875.99 (+0.5%)
|
3,442.31
est: 3,950.59 (-12.9%)
|
1,969.23
est: 1,843.28 (+6.8%)
|
4,466.05
est: 3,920.82 (+13.9%)
|
6,448.11
6,049.23 – 6,879.83
+64.5% YoY
|
7,438.56
6,115.75 – 9,491.10
+15.4% YoY
|
8,881.26
8,301.81 – 9,787.71
+19.4% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-15 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hyong-Gi Kim | Co-CEO & Internal Director | — | male |
| Ji-Hoon Choi | Director of Legal Affairs | — | male |
| Jin-seok Seo | Co-CEO & Inside Co-Chairman of the Board | — | male |
| Min-Cheol Shin | CFO, Director of Finance & Inside Director | — | male |
| Stephen Yeum | Founder | — | male |
| Woo-Sung Kee | Co-CEO & Internal Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 068270.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
